Answers are grounded in this paper and cite their sources.
INTRODUCTION: Liver metastasis (LM) confers a poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Although EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line treatment, the optimal approach for this high-risk subgroup remains uncertain. This study compared the efficacy and safety of EGFR-TKI monotherapy versus EGFR-TKI combined with chemotherapy in EGFR-mutant NSCLC patients with LM. PATIENTS AND METHODS: We retrospectively analyzed 98 patients with stage IV EGFR-mutant NSCLC and LM treated between 2020 and 2025. Fifty-nine patients received EGFR-TKI monotherapy, and 39 received EGFR-TKI plus platinum-based chemotherapy. Propensity score matching (PSM) was performed to balance baseline characteristics. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared by Cox regression. Safety profiles were analyzed according to CTCAE v5.0. RESULTS: After PSM, baseline characteristics were well balanced. The combination group achieved a higher objective response rate (59.0% vs 35.6%; P = .038), a higher disease control rate (100% vs 86.4%; P = .020), and a longer median PFS (14.0 vs 10.4 months; HR, 0.47; 95% CI, 0.26-0.86; P = .012). Median OS was 30.0 months with combination therapy versus 24.0 months with monotherapy (HR, 0.78; 95% CI, 0.39-1.55; P = .474). Severe (grade ≥3) adverse events were infrequent and comparable between groups, with no treatment-related deaths. CONCLUSION: First-line EGFR-TKI plus chemotherapy significantly improved PFS and disease control without added toxicity, suggesting a promising therapeutic strategy for EGFR-mutant NSCLC with LM.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: